Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Novo Nordisk

Status and phase

Completed

Phase 2

Conditions

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: placebo

Drug: liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT01508923

NN2211-1332

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes mellitus
Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included
Body Mass Index (BMI) maximum 35 kg/m^2
Fasting plasma glucose 7-15 mmol/l, both inclusive

Exclusion criteria

Impaired liver function
Impaired renal function
Anaemia
Cardiac disease
Uncontrolled treated/untreated hypertension
Recurrent major hypoglycaemia as judged by the Investigator
Known or suspected allergy to trial product or related products
Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures
Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
Loss of more than 400 ml blood during the three months prior to study start
Allergy to paracetamol